Cooperative Agreement NU51PS004633

This federal Cooperative Agreement award of $1,800,000 from the National Center for HIV/AIDS (CFDA 93.940 - HIV Prevention Activities Health Department Based) will support the Sacramento County Department of Health Services, Division of Public Health in expanding access to HIV/STI prevention, testing, and care services for priority populations in Sacramento County. Key products and services to be delivered include: Expanding the Sexual Health Clinic's clinical infrastructure and service delivery...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $814,790 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the immune mechanisms underlying hepatitis B virus (HBV) surface antigen (HBsAg) clearance in chronic HBV patients. The research aims to uncover parallels between mouse models and clinical studies of HBsAg clearance,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,279,005 to The Johns Hopkins University to conduct research on hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional silencing, with a focus on comparing HBV mono-infection and HBV/HIV co-infection. The 5-year project aims to uncover the mechanisms underlying cccDNA transcriptional...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $234,735 to The Regents of the University of California, San Francisco (UCSF) to conduct research on improving immune responses against hepatitis B virus (HBV) infection. The research aims to investigate the mechanisms behind age-related differences in the body's ability to clear HBV surface antigen, which...

This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...

This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, aims to develop a low-cost, rapid antigen test for active hepatitis C virus (HCV) infection. The total funding amount is $272,133, with an award date of June 18, 2025 and an ultimate completion date of May 31, 2027. The project will characterize the binding kinetics of HCV core antigen-specific monoclonal antibodies and use the...

The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA) awarded a $450,000 Project Grant under the HIV-Related Training and Technical Assistance program (CFDA 93.145) to Cares Community Health, a non-profit organization based in Sacramento, California. The grant funding will support Cares Community Health's efforts to enhance HIV prevention, care, and treatment services through comprehensive educational and capacity-building initiatives for...

The Project Grant award R01AI179309 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a 5-year, $762,072 translational research project to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV). The research aims to leverage expertise and collaboration to transform existing short-acting oral antiviral drugs into a new long-acting injectable HBV therapy. Key goals...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $621,698 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Southern California. The goal of this 5-year research project is to investigate how hepatitis B virus (HBV) transmitted from infected mothers to their children affects the offspring's immune response and promotes chronic HBV infection. The researchers will identify specific maternal HBV factors that enable...